Welcome to our dedicated page for Chemomab Therapeutics Ltd. American Depositary Share news (Ticker: $CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics Ltd. American Depositary Share stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chemomab Therapeutics Ltd. American Depositary Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chemomab Therapeutics Ltd. American Depositary Share's position in the market.
Chemomab Therapeutics (Nasdaq: CMMB) has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule. The company has until November 4, 2024, to ensure that the closing bid price of its American Depositary Shares (ADSs) is at least $1.00 per ADS for a minimum of 10 consecutive trading days. If the requirement is met, Nasdaq will confirm compliance, allowing Chemomab to maintain its listing on the Nasdaq Capital Market under the symbol 'CMMB'.
Chemomab Therapeutics (Nasdaq: CMMB) will have Dr. Adi Mor, the CEO, present at the Aegis Virtual Conference on May 7, 2024, discussing innovative therapeutics for fibro-inflammatory diseases. The presentation will be webcast live, offering further insights into the company's endeavors.
